Pharmaceutical Business review

Baxter to recall heparin vials and products

The company initially recalled nine lots of heparin sodium injection multi-dose vials on January 17, 2008 as a precautionary measure due to a higher than usual number of reports of adverse patient reactions involving the product and suspended production earlier this month.

Although the vast majority of the reports of adverse reactions have been associated with the multi-dose products, Baxter is taking the precautionary step of recalling all remaining heparin sodium injection and heparin flush products that are currently on the market.

In addition to the previously recalled lots of heparin sodium injection 1000 units/mL 10mL and 30mL multi- dose vials, Baxter’s recall will now include the remaining lots of those products and heparin sodium injection 5000 units/mL 10mL multi-dose vials, heparin sodium injection 10,000 units/mL 4mL multi-dose vials, heparin sodium injection 1000 USP units/mL, 5000 USP units/mL, and 10,000 USP units/mL single-dose vials, and all Hep-Lock and Hep-Lock U/P, 10 USP units/mL and 100 USP units/mL vials, both preserved and preservative-free.